Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 19, 2017

Thermo Fisher Scientific Announces New Chromatography Technologies

The company announced its new ISQ EC Single Quadrupole mass spectrometer and the new range of Thermo Scientific MAbPac RP 1-mm columns.

On June 19, 2017 Thermo Fisher Scientific announced new technologies designed to allow analytical chemists to obtain high-resolution separations. The company is displaying the new technologies at the 46th International Symposium on High Performance Liquid Phase Separations and Related Techniques from June 18–22, 2017, at the Prague Congress Centre.

The new Thermo Scientific ISQ EC Single Quadrupole mass spectrometer (MS) integrates with an existing ion chromatography (IC) or high performance liquid chromatography (HPLC) system and provides small molecule sensitivity and mass confirmation. The Chromeleon Chromatography Data Software platform has embedded ISQ EC MS instrument control, which enables users to minimize time spent on new MS user training. The instrument also enables users to analyze a range of simple and complex sample matrices.

The new range of Thermo Scientific MAbPac RP 1-mm columns are designed for high-performance, reversed-phase chromatography characterization of monoclonal antibodies, fragments, variants, antibody drug conjugates, and proteins. With a 1-mm inner diameter, the new columns provide sensitive analyses of very small sample volumes at low flow rates for direct injection into the LC-MS. The columns include a polymeric resin with an optimized pore size and thermal and pH stability.

Source: Thermo Fisher Scientific 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.